What is Palvella Therapeutics, Inc.'s earnings per share (EPS)?

Palvella Therapeutics, Inc. (PVLA) reported diluted earnings per share of -$3.71 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Palvella Therapeutics, Inc. (PVLA) Financials

PVLA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$41.7M -139.3% YoY

EPS (Diluted) -$3.71 YoY not available

Operating Cash Flow -$25.0M -130.7% YoY

Market Cap $1.9B as of Oct 8, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 8.7x on $216.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PVLA SEC filings page.

This page shows Palvella Therapeutics, Inc. (PVLA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PVLA FY2025 2026-10-03

Palvella operates as a development-stage business: rising research spending is driving larger losses while reported liquidity remains substantial.

Cash conversion is deteriorating alongside investment intensity: operating cash outflow widened from $10.8M in FY2024 to $25.0M in FY2025 as research and development spending increased from $8.2M to $22.8M. That pairing indicates the deeper cash use is tied mainly to expanding development activity, not merely weaker administrative efficiency.

The income statement and cash flow agree on the direction: FY2025 showed a net loss of $41.7M alongside operating cash outflow of $25.0M, so reported losses translated into substantial cash consumption rather than being offset by non-cash accounting effects.

The balance sheet is becoming less insulated: total assets fell from $88.2M in FY2024 to $59.6M in FY2025 while total liabilities rose from $25.6M to $31.6M; debt-to-equity consequently moved from 0.4x to 1.1x. Current assets still exceeded current liabilities by 5.2x, and reported cash, equivalents, and investments equaled 27.8 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Palvella Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Palvella Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Palvella Therapeutics, Inc. reported a net loss of $41.7M while operations used $25.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$21.9M

YoY-130.9%

QoQ-38.7%

Palvella Therapeutics, Inc. reported -$21.9M in net income in Q2 2026. This represents a decrease of 130.9% from the same quarter a year earlier. Against the prior quarter it is down 38.7%.

EPS (Diluted)

-$1.52

YoY-76.7%

QoQ-26.7%

Palvella Therapeutics, Inc. earned -$1.52 per diluted share (EPS) in Q2 2026. This represents a decrease of 76.7% from the same quarter a year earlier. Against the prior quarter it is down 26.7%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$187.8M

YoY+166.6%

QoQ-9.0%

5Y CAGR+9.5%

10Y CAGR+16.6%

Palvella Therapeutics, Inc. held $187.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

14M

YoY+30.3%

QoQ+0.5%

5Y CAGR-26.4%

10Y CAGR-10.4%

Palvella Therapeutics, Inc. had 14M shares outstanding in Q2 2026. This represents an increase of 30.3% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-10.1%

YoY+9.7pp

QoQ-3.3pp

Palvella Therapeutics, Inc.'s ROE was -10.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 9.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$12.5M

YoY+143.7%

QoQ+33.6%

Palvella Therapeutics, Inc. invested $12.5M in research and development in Q2 2026. This represents an increase of 143.7% from the same quarter a year earlier. Against the prior quarter it is up 33.6%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

PVLA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PVLA quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	N/A	N/A	$42.8M+65.3%	$25.9M-17.6%	$31.4M+7.1%	$29.3M-36.6%	$46.3M+59.0%	$29.1M+15.1%	$25.3M+333.5%	$5.8M+98.9%	$2.9M-45.4%	$5.4M-56.8%	$12.4M
R&D Expenses	N/A	$22.8M+180.2%	$8.2M-7.3%	$8.8M-83.4%	$53.0M-20.5%	$66.7M+43.3%	$46.5M-15.4%	$55.0M+32.6%	$41.5M+86.2%	$22.3M+13.1%	$19.7M+138.9%	$8.2M+47.2%	$5.6M-40.5%	$9.4M
SG&A Expenses	N/A	$15.8M+165.2%	$5.9M+93.2%	$3.1M-81.2%	$16.4M-1.2%	$16.6M-0.7%	$16.7M-9.4%	$18.4M0.0%	$18.4M+4.9%	$17.6M+97.8%	$8.9M+6.2%	$8.4M+20.2%	$7.0M+182.9%	$2.5M
Operating Income	N/A	-$38.6M-173.9%	-$14.1M-18.8%	-$11.9M+72.7%	-$43.5M+16.1%	-$51.8M-52.8%	-$33.9M-24.9%	-$27.2M+11.9%	-$30.8M-111.3%	-$14.6M+35.9%	-$22.8M-66.4%	-$13.7M-90.1%	-$7.2M-1399.7%	$554K
EBITDA	N/A	N/A	N/A	-$10.0M+75.5%	-$40.7M+17.6%	-$49.4M-55.2%	-$31.8M-19.8%	-$26.6M+12.2%	-$30.3M-112.7%	-$14.2M+36.5%	-$22.4M-67.5%	-$13.4M-95.8%	-$6.8M-827.9%	$939K
Interest Expense	N/A	$0-100.0%	$430K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$185K-93.0%	$2.7M+437.5%	$494K
Income Tax	N/A	$0	$0	$0	$0	$0-100.0%	$164K	$0+100.0%	-$312K-128.3%	$1.1M+580.9%	$162K-20.5%	$204K+1132688.9%	-$18	N/A
Net Income	N/A	-$41.7M-139.3%	-$17.4M-193.3%	$18.7M+156.2%	-$33.3M+27.2%	-$45.7M-22.9%	-$37.2M-46.2%	-$25.5M+4.8%	-$26.8M-51.6%	-$17.6M+22.6%	-$22.8M-62.2%	-$14.1M-42.7%	-$9.8M-14980.0%	$66K
EPS (Basic)	N/A	-$3.71+52.6%	-$7.83-457.5%	$2.19+586.7%	-$0.45+36.6%	-$0.71-4.4%	-$0.68	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$4.83	-$3.71	-$7.83	$2.17	N/A	-$0.71-4.4%	-$0.68	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	11M	2M	2M	N/A	65M+18.5%	54M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%
R&D Expenses	$12.5M+143.7%	$9.3M+129.1%	N/A	$6.5M+105.2%	$5.1M+254.9%	$4.1M+314.0%	N/A	$3.2M-66.8%
SG&A Expenses	$8.9M+116.2%	$5.5M+45.4%	N/A	$3.6M+94.1%	$4.1M+181.9%	$3.8M+389.9%	N/A	$1.9M-72.5%
Operating Income	-$21.4M-131.4%	-$14.9M-88.7%	N/A	-$10.2M-101.0%	-$9.3M-218.1%	-$7.9M-347.5%	N/A	-$5.1M+57.1%
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$5.1M+54.3%
Interest Expense	$2.0M	$1.1M+42.7%	N/A	$0-100.0%	$0-100.0%	$752K+774.4%	N/A	$220K
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$21.9M-130.9%	-$15.8M-92.6%	N/A	-$11.3M-67.5%	-$9.5M-127.0%	-$8.2M-222.8%	N/A	-$6.8M+37.0%
EPS (Basic)	-$1.52-76.7%	-$1.20-62.2%	-$1.08-206.9%	-$1.03+73.9%	-$0.86+65.2%	-$0.74+51.9%	$1.01+2625.0%	-$3.94+54.7%
EPS (Diluted)	-$1.52-76.7%	-$1.20-62.2%	-$1.08-206.9%	-$1.03	-$0.86	-$0.74	$1.01	-$3.94
Diluted Shares (Avg)	14M+29.9%	13M+18.8%	N/A	11M	11M	11M	N/A	2M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

PVLA Balance Sheet

PVLA quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$59.6M-32.5%	$88.2M+1069.0%	$7.5M-92.1%	$95.5M-37.8%	$153.6M+46.2%	$105.0M-25.6%	$141.1M-0.2%	$141.3M+36.1%	$103.9M+196.3%	$35.1M+3.3%	$34.0M+55.3%	$21.9M+200.4%	$7.3M
Current Assets	$59.0M-33.1%	$88.2M+1069.0%	$7.5M-89.7%	$73.4M-42.5%	$127.6M+68.5%	$75.7M-34.2%	$115.0M-15.0%	$135.4M+50.8%	$89.8M+174.8%	$32.7M+3.2%	$31.7M+59.9%	$19.8M+310.9%	$4.8M
Cash & Equivalents	$58.0M-30.6%	$83.6M+1037.4%	$7.3M-81.0%	$38.6M-67.2%	$117.8M+67.2%	$70.4M+13.1%	$62.3M-16.8%	$74.9M+97.7%	$37.9M+29.0%	$29.4M0.0%	$29.4M+58.9%	$18.5M+400.7%	$3.7M
Short-Term Investments	$0	$0	$0-100.0%	$20.5M	$0	$0-100.0%	$41.9M-21.3%	$53.2M+53.2%	$34.8M	$0	$0	$0	$0
Accounts Receivable	$0-100.0%	$358K	$0-100.0%	$5.8M+75.4%	$3.3M+94.2%	$1.7M-74.9%	$6.8M+151.3%	$2.7M-82.6%	$15.5M+27173.7%	$57K	$0	$0-100.0%	$482K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$9.9M	$0	$0	$0	$0
Total Liabilities	$31.6M+23.2%	$25.6M-68.8%	$82.0M-56.7%	$189.3M+84.1%	$102.8M+39.0%	$74.0M-17.6%	$89.7M-11.5%	$101.4M+9.8%	$92.4M+838.9%	$9.8M+248.6%	$2.8M-26.7%	$3.9M-42.4%	$6.7M
Current Liabilities	$11.3M-5.8%	$12.0M+410.1%	$2.4M-93.5%	$36.6M-27.6%	$50.6M+128.3%	$22.1M-18.0%	$27.0M-43.8%	$48.1M+5.0%	$45.8M+446.2%	$8.4M+199.5%	$2.8M-20.5%	$3.5M+98.9%	$1.8M
Non-Current Liabilities	$20.2M+48.9%	$13.6M-82.9%	$79.7M-47.8%	$152.7M+192.3%	$52.2M+0.8%	$51.8M-17.4%	$62.7M+17.6%	$53.3M+14.5%	$46.6M+3099.1%	$1.5M+6004.3%	$24K-92.9%	$334K-93.2%	$4.9M
Total Equity	$28.0M-55.3%	$62.6M+184.1%	-$74.5M+20.6%	-$93.8M-284.8%	$50.8M+63.6%	$31.0M-39.6%	$51.4M+28.6%	$39.9M+246.6%	$11.5M-54.3%	$25.2M-19.0%	$31.1M+72.9%	$18.0M+2978.0%	$585K
Retained Earnings	-$135.4M-44.5%	-$93.7M-22.8%	-$76.3M+73.7%	-$290.4M-12.9%	-$257.1M-21.6%	-$211.4M-21.4%	-$174.2M-18.4%	-$147.1M-22.2%	-$120.3M-17.2%	-$102.7M-28.5%	-$79.9M-21.4%	-$65.8M-17.6%	-$56.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$253.5M+243.8%	$263.8M+232.0%	$59.6M-32.5%	$66.9M+226.2%	$73.7M+194.4%	$79.4M+169.3%	$88.2M+1069.0%	$20.5M-65.4%
Current Assets	$253.0M+243.1%	$263.2M+231.4%	$59.0M-33.1%	$66.9M	$73.7M	$79.4M	$88.2M+1069.0%	N/A
Cash & Equivalents	$187.8M+166.6%	$206.4M+172.9%	$58.0M-30.6%	$63.6M+228.3%	$70.4M+257.0%	$75.6M+296.3%	$83.6M+1037.4%	$19.4M-41.1%
Short-Term Investments	$62.8M	$55.5M	$0	$0	$0	$0	$0	$0-100.0%
Accounts Receivable	N/A	N/A	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$358K	$373K-64.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$36.6M+41.1%	$31.4M+31.8%	$31.6M+23.2%	$28.3M-73.8%	$26.0M-75.5%	$23.9M-77.6%	$25.6M-68.8%	$107.9M+273.9%
Current Liabilities	$11.9M+24.2%	$9.1M+1.5%	$11.3M-5.8%	$10.3M+142.4%	$9.6M+51.5%	$9.0M+19.2%	$12.0M+410.1%	$4.3M-85.3%
Non-Current Liabilities	$24.7M+51.0%	$22.3M+50.1%	$20.2M+48.9%	$17.9M-82.7%	$16.4M-83.6%	$14.9M-84.9%	$13.6M-82.9%	$103.7M
Total Equity	$216.9M+353.9%	$232.3M+318.0%	$28.0M-55.3%	$38.7M+144.3%	$47.8M+159.1%	$55.6M+172.3%	$62.6M+184.1%	-$87.4M-386.5%
Retained Earnings	-$173.1M-55.4%	-$151.2M-48.4%	-$135.4M-44.5%	-$122.7M+62.4%	-$111.4M+65.6%	-$101.9M+68.1%	-$93.7M-22.8%	-$326.3M-5.1%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

PVLA Cash Flow Statement

PVLA quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$36.5M	-$25.0M-130.7%	-$10.8M+20.9%	-$13.7M+77.1%	-$59.9M-682.4%	-$7.7M+83.3%	-$45.9M+12.5%	-$52.5M-4821.9%	-$1.1M-102.1%	$49.8M+445.8%	-$14.4M-13.2%	-$12.7M-84254.5%	-$15K+99.5%	-$3.1M
Depreciation & Amortization	N/A	N/A	N/A	$1.9M-31.3%	$2.8M+12.6%	$2.5M+17.1%	$2.1M+250.0%	$600K+5.3%	$570K+54.5%	$369K+2.2%	$361K+17.2%	$308K-16.1%	$367K-4.6%	$385K
Stock-Based Compensation	N/A	$6.4M+671.2%	$830K+37.6%	$603K-86.3%	$4.4M-15.6%	$5.2M+2.5%	$5.1M-5.3%	$5.4M+8.7%	$4.9M+62.3%	$3.0M+59.9%	$1.9M+63.6%	$1.2M+103.8%	$571K	N/A
Capital Expenditures	N/A	N/A	N/A	$171K-83.6%	$1.0M+9.7%	$949K-65.2%	$2.7M+10.7%	$2.5M+45.0%	$1.7M-12.9%	$1.9M+248.2%	$560K-9.8%	$621K+132.1%	$267K+440.5%	$49K
Free Cash Flow	N/A	N/A	N/A	-$13.9M+77.2%	-$61.0M-608.2%	-$8.6M+82.3%	-$48.6M+11.5%	-$54.9M-1887.3%	-$2.8M-105.8%	$47.8M+419.8%	-$14.9M-12.2%	-$13.3M-4617.8%	-$282K+91.0%	-$3.1M
Investing Cash Flow	N/A	N/A	N/A	$12.0M+156.5%	-$21.2M-2137.7%	-$949K-102.4%	$39.2M+298.6%	$9.8M+210.9%	-$8.9M+80.7%	-$45.9M	N/A	N/A	N/A	N/A
Financing Cash Flow	$216.2M	-$660K-100.8%	$87.1M+1641.8%	$5.0M-30.7%	$7.2M-87.8%	$59.1M+484.5%	$10.1M-68.6%	$32.2M-33.7%	$48.5M+1086.1%	$4.1M	N/A	N/A	$21K	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$12.8M-136.4%	-$10.9M-60.5%	-$4.9M+8.7%	-$7.9M-187.3%	-$5.4M-239.0%	-$6.8M-514.2%	-$5.4M-126.4%	-$2.7M+71.8%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%
Stock-Based Compensation	$5.2M+259.7%	$3.4M+208.6%	N/A	$1.8M+799.5%	$1.4M+560.4%	$1.1M+649.3%	N/A	$199K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$2.7M+72.0%
Investing Cash Flow	-$7.0M	-$55.4M	N/A	N/A	$0-100.0%	$0-100.0%	N/A	$142K+107.2%
Financing Cash Flow	$1.3M+266.8%	$214.7M+17964.5%	-$49K-100.1%	$242K-90.0%	$349K-96.5%	-$1.2M	$74.8M+606.0%	$2.4M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PVLA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PVLA quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	N/A	N/A	-27.7%	-167.8%	-165.0%	-115.7%	-58.7%	-105.9%	-57.7%	-390.3%	-466.6%	-134.2%	4.5%
Net Margin	N/A	N/A	43.7%	-128.5%	-145.6%	-127.0%	-55.0%+36.9pp	-91.9%-22.1pp	-69.8%	-391.0%	-479.5%	-183.6%	0.5%
Return on Equity	-149.1%-121.2pp	-27.9%	N/A	N/A	-90.1%+29.9pp	-120.0%-70.4pp	-49.6%+17.4pp	-67.0%+86.2pp	-153.2%-62.8pp	-90.4%-45.2pp	-45.2%+9.5pp	-54.7%-66.0pp	11.3%
Return on Assets	-70.0%-50.3pp	-19.8%-267.4pp	247.6%+282.5pp	-34.8%-5.1pp	-29.8%+5.7pp	-35.4%-17.4pp	-18.1%+0.9pp	-18.9%-1.9pp	-17.0%+48.0pp	-65.0%-23.6pp	-41.4%+3.6pp	-45.1%-46.0pp	0.9%
Current Ratio	5.20-2.1x	7.33+4.1x	3.20+1.2x	2.01-0.5x	2.52-0.9x	3.42-0.8x	4.26+1.4x	2.82+0.9x	1.96-1.9x	3.90-7.4x	11.32+5.7x	5.63+2.9x	2.73
Debt-to-Equity	1.13+0.7x	0.41	N/A	N/A	2.03-0.4x	2.38+0.6x	1.75-0.8x	2.54-5.5x	8.02+7.6x	0.39+0.3x	0.09-0.1x	0.21-11.2x	11.44
Asset Turnover	N/A	N/A	5.67+5.4x	0.27+0.1x	0.20-0.1x	0.280.0x	0.33+0.1x	0.210.0x	0.24+0.1x	0.17+0.1x	0.09-0.2x	0.25-1.5x	1.71
FCF Margin	N/A	N/A	-32.4%	-235.4%	-27.4%	-165.8%	-118.7%	-9.5%	189.1%	-256.3%	-454.5%	-5.3%+19.9pp	-25.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-10.1%+9.7pp	-6.8%+7.9pp	N/A	-29.3%	-19.8%	-14.7%	N/A	N/A
Return on Assets	-8.6%+4.2pp	-6.0%+4.3pp	N/A	-17.0%+16.1pp	-12.8%+3.8pp	-10.3%-1.7pp	N/A	-33.0%-14.9pp
Current Ratio	21.18+13.5x	28.88+20.0x	5.20-2.1x	6.49	7.67	8.84	7.33+4.1x	N/A
Debt-to-Equity	0.17-0.4x	0.14-0.3x	1.13+0.7x	0.73	0.54	0.43	0.41	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.00-0.3x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Palvella Therapeutics, Inc. PVLA	FY2025	N/A	-$41.7M	N/A	$1.9B	—
Rigel Pharmaceuticals Inc. (New) RIGL	FY2025	$294.3M	$367.0M	N/A	$896.4M	62/100
Savara Inc. SVRA	FY2025	N/A	-$118.8M	N/A	$1.0B	—
AnaptysBio, Inc. ANAB	FY2025	$234.6M	-$13.2M	-5.6%	$1.4B	80/100
Keros Therapeutics, Inc. KROS	FY2025	$243.9M	$87.0M	35.7%	$222.3M	91/100
Rezolute, Inc. RZLT	FY2026	N/A	-$77.6M	N/A	$423.6M	—

Where Palvella Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Palvella Therapeutics, Inc. profitable?

No, Palvella Therapeutics, Inc. (PVLA) reported a net income of -$41.7M in fiscal year 2025.

What is Palvella Therapeutics, Inc.'s return on equity (ROE)?

Palvella Therapeutics, Inc. (PVLA) has a return on equity of -149.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Palvella Therapeutics, Inc.'s operating cash flow?

Palvella Therapeutics, Inc. (PVLA) recorded an outflow of $25.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Palvella Therapeutics, Inc.'s total assets?

Palvella Therapeutics, Inc. (PVLA) had $59.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Palvella Therapeutics, Inc. spend on research and development?

Palvella Therapeutics, Inc. (PVLA) invested $22.8M in research and development during fiscal year 2025.

How many shares does Palvella Therapeutics, Inc. have outstanding?

Palvella Therapeutics, Inc. (PVLA) had 14M shares outstanding as of fiscal year 2025.

What is Palvella Therapeutics, Inc.'s current ratio?

Palvella Therapeutics, Inc. (PVLA) had a current ratio of 5.20 as of fiscal year 2025, which is generally considered healthy.

What is Palvella Therapeutics, Inc.'s debt-to-equity ratio?

Palvella Therapeutics, Inc. (PVLA) had a debt-to-equity ratio of 1.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Palvella Therapeutics, Inc.'s return on assets (ROA)?

Palvella Therapeutics, Inc. (PVLA) had a return on assets of -70.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Palvella Therapeutics, Inc.'s P/E ratio?

Palvella Therapeutics, Inc. (PVLA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.9B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Palvella Therapeutics, Inc.'s price-to-sales ratio?

Palvella Therapeutics, Inc. (PVLA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.9B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Palvella Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Palvella Therapeutics, Inc. (PVLA) held $58.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $25.0M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Palvella Therapeutics, Inc.'s Piotroski F-Score?

Palvella Therapeutics, Inc. (PVLA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Palvella Therapeutics, Inc.'s earnings high quality?

Palvella Therapeutics, Inc. (PVLA) reported a net loss of $41.7M while operations used $25.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.